Last Updated: August 11, 2026

Details for Patent: 8,143,240

Name: Drug Patent Intelligence for US Patent 8143240
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,143,240 protect, and when does it expire?

Patent 8,143,240 protects WINLEVI and is included in one NDA.

This patent has seventeen patent family members in fourteen countries.

Summary for Patent: 8,143,240

Title:	17α, 21-dihydroxypregnene esters as antiandrogenic agents
Abstract:	17α,21-Dihydroxypregna-4,9-diene-3,20-dione and 17α,21-dihydroxypregna-4-ene-3,20-dione 17 and/or 21 esters of having remarkable antiandrogenic activity, and the processes for the preparation thereof.
Inventor(s):	Mauro Ajani, Luigi Moro
Assignee:	Cassiopea SpA
Application Number:	US12/457,870
Patent Claim Types: see list of patent claims	Use; Composition;
Patent landscape, scope, and claims:	error: insufficient information More… ↓ ⤷ Start Trial

Drugs Protected by US Patent 8,143,240

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sun Pharm	WINLEVI	clascoterone	CREAM;TOPICAL	213433-001	Aug 26, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				METHOD OF TREATING ACNE VULGARIS WITH TOPICALLY APPLIED CORTEXOLONE 17A-PROPIONATE	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foreign Priority and PCT Information for Patent: 8,143,240

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Italy	MI2001A1762	Aug 10, 2001

International Family Members for US Patent 8,143,240

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	289318	⤷ Start Trial
Australia	2002328956	⤷ Start Trial
Canada	2454675	⤷ Start Trial
China	1246328	⤷ Start Trial
China	1541220	⤷ Start Trial
Germany	60203013	⤷ Start Trial
Denmark	1421099	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.